心脏 Amyloidosis 的心力衰竭管理:朝着一个范式的转变
Giorgia Panichella1, Alberto Aimo2,3, Vincenzo Castiglione2,3
1Department of Experimental and Clinical Medicine, University of Florence Florence, Italy.
Cardiac failure review
|July 31, 2025
概括
心脏粉症 (CA) 和心力衰竭 (HF) 的管理正在发展. 神经激素抗剂,一旦禁用,现在可能会使CA患者受益,改变治疗范式以改善结果.
科学领域:
- 心脏病学 心脏病学
- 内部医学 内部医学
- 生物医学科学 生物医学科学
背景情况:
- 随着流行病学的变化,心力衰竭 (HF) 和心肌粉症 (CA) 带来了复杂的临床挑战.
- CA越来越多地被认为超出了HF,具有保存的喷射分数,也影响了喷射分数减少的患者.
研究的目的:
- 审查CA中神经激素激活对疾病进展和管理的影响.
- 探索神经激素对抗剂在CA治疗中的不断变化的作用.
- 提供当前治疗策略的概述和针对CA的HF的个性化护理.
主要方法:
- 对CA中HF当前治疗方法的文献综述.
- 分析神经激素激活和调节在CA中的作用.
- 关于CA患者的神经激素抗剂的最新证据的审查.
主要成果:
- CA呈现出多样化的左心室喷射分数配置文件,不仅限于保留功能.
- 历史上禁用的神经激素抗剂在CA中显示出潜在的治疗益处.
- 个性化护理策略对于管理CA中的HF复杂性至关重要.
结论:
- 对CA及其对高频的影响的理解正在不断发展.
- 神经激素调制是CA治疗进步的一个关键领域.
- 治疗策略的范式转变,包括使用神经激素抗剂,正在为患有HF的CA患者出现.
相关概念视频
Heart Failure V: Medical Management
25
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
25
Cardiomyopathy V: Interprofessional Care
34
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
34
Cardiomyopathy VI: Nursing Management
44
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
44
Cardiomyopathy II: Dilated Cardiomyopathy
23
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
23
Myocarditis III: Medical Management
16
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
16
Cardiomyopathy III: Hypertrophic Cardiomyopathy
52
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
52


